Summary
9.71 -0.23(-2.27%)05/08/2024
Vir Biotechnology Inc (VIR)
Vir Biotechnology Inc (VIR)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -2.89 | 17.16 | 4.32 | 8.91 | 17.30 | -58.99 | 0.00 | -29.39 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 9.90 | |
| Open | 10.34 | |
| High | 10.46 | |
| Low | 9.86 | |
| Volume | 613,520 | |
| Change | -0.30 | |
| Change % | -2.89 | |
| Avg Volume (20 Days) | 742,916 | |
| Volume/Avg Volume (20 Days) Ratio | 0.83 | |
| 52 Week Range | 7.61 - 27.48 | |
| Price vs 52 Week High | -63.97% | |
| Price vs 52 Week Low | 30.09% | |
| Range | -4.26 | |
| Gap Up/Down | -0.20 | |
Fundamentals | ||
| Market Capitalization (Mln) | 1,351 | |
| EBIDTA | -126,076,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 77.14 | |
| Book Value | 6.6980 | |
| Earnings Per Share | -0.7960 | |
| EPS Estimate Current Quarter | 0.0200 | |
| EPS Estimate Next Quarter | -0.0100 | |
| EPS Estimate Current Year | 1.6100 | |
| EPS Estimate Next Year | 0.3800 | |
| Diluted EPS (TTM) | -0.7960 | |
| Revenues | ||
| Profit Marging | -0.3598 | |
| Operating Marging (TTM) | -0.6179 | |
| Return on asset (TTM) | -0.1020 | |
| Return on equity (TTM) | -0.1212 | |
| Revenue TTM | 284,401,984 | |
| Revenue per share TTM | 2.2050 | |
| Quarterly Revenue Growth (YOY) | 52.7430 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | -196,511,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 14.0647 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 6.5121 | |
| Revenue Enterprise Value | 17.0149 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 130,880,000 | |
| Shares Float | 71,603,226 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 13.07 | |
| Institutions (%) | 73.41 | |
05/07 11:01 EST - Zacks Investment Research
Wall Street Analysts Think Vir Biotechnology (VIR) Could Surge 188.65%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 188.7% in Vir Biotechnology (VIR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Think Vir Biotechnology (VIR) Could Surge 188.65%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 188.7% in Vir Biotechnology (VIR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
05/03 00:35 EST - Seeking Alpha
Vir Biotechnology, Inc. (VIR) Q1 2024 Earnings Call Transcript
Vir Biotechnology, Inc. (NASDAQ:VIR ) Q1 2024 Earnings Conference Call May 2, 2024 4:30 PM ET Company Participants Sasha Damouni Ellis - Executive Vice President, Chief Corporate Affairs Officer Marianne De Backer - Chief Executive Officer Carrie Huang - Senior Vice President, Clinical Research and Interim Chief Medical Officer Sung Lee - Chief Financial Officer Conference Call Participants Gena Wang - Barclays Paul Choi - Goldman Sachs Alec Stranahan - Bank of America Phil Nadeau - TD Cowen Patrick Trucchio - H.C. Wainwright Rosa Chen - Leerink Partners Joseph Stringer - Needham & Company Eric Joseph - JP Morgan Michaels Ulz - Morgan Stanley Operator Hello.
Vir Biotechnology, Inc. (VIR) Q1 2024 Earnings Call Transcript
Vir Biotechnology, Inc. (NASDAQ:VIR ) Q1 2024 Earnings Conference Call May 2, 2024 4:30 PM ET Company Participants Sasha Damouni Ellis - Executive Vice President, Chief Corporate Affairs Officer Marianne De Backer - Chief Executive Officer Carrie Huang - Senior Vice President, Clinical Research and Interim Chief Medical Officer Sung Lee - Chief Financial Officer Conference Call Participants Gena Wang - Barclays Paul Choi - Goldman Sachs Alec Stranahan - Bank of America Phil Nadeau - TD Cowen Patrick Trucchio - H.C. Wainwright Rosa Chen - Leerink Partners Joseph Stringer - Needham & Company Eric Joseph - JP Morgan Michaels Ulz - Morgan Stanley Operator Hello.
05/02 19:06 EST - Zacks Investment Research
Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Tops Revenue Estimates
Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.99. This compares to loss of $1.06 per share a year ago.
Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Tops Revenue Estimates
Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.99. This compares to loss of $1.06 per share a year ago.
04/24 13:01 EST - Zacks Investment Research
What Makes Vir Biotechnology (VIR) a New Buy Stock
Vir Biotechnology (VIR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
What Makes Vir Biotechnology (VIR) a New Buy Stock
Vir Biotechnology (VIR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
04/11 16:30 EST - Business Wire
Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the first quarter ended March 31, 2024, on May 2, 2024. The Company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on May 2, 2024. The corporate update and financial results will be provided via a press release after market close and will be accessible under Press Releases in the Investors section of th.
Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the first quarter ended March 31, 2024, on May 2, 2024. The Company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on May 2, 2024. The corporate update and financial results will be provided via a press release after market close and will be accessible under Press Releases in the Investors section of th.
03/19 14:58 EST - InvestorPlace
From Six Figures to Seven: 3 Biotech Stocks Set to Make Millionaires
Given the current risk-on sentiment, it is perhaps an ideal time for investors to scoop up some of the top biotech stocks. The stock market is booming, and with investors looking to take on more risk, a potential surge in biotech stocks seems likely.
From Six Figures to Seven: 3 Biotech Stocks Set to Make Millionaires
Given the current risk-on sentiment, it is perhaps an ideal time for investors to scoop up some of the top biotech stocks. The stock market is booming, and with investors looking to take on more risk, a potential surge in biotech stocks seems likely.
02/27 23:56 EST - Seeking Alpha
Vir Biotechnology: Making Progress In Hepatitis B And Hepatitis Delta
Vir Biotechnology is developing treatments for Hepatitis B, Hepatitis Delta, HIV, and COVID, among others.
Vir Biotechnology: Making Progress In Hepatitis B And Hepatitis Delta
Vir Biotechnology is developing treatments for Hepatitis B, Hepatitis Delta, HIV, and COVID, among others.
02/23 10:56 EST - Zacks Investment Research
Wall Street Analysts Believe Vir Biotechnology, Inc. (VIR) Could Rally 186.41%: Here's is How to Trade
The consensus price target hints at an 186.4% upside potential for Vir Biotechnology, Inc. (VIR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Believe Vir Biotechnology, Inc. (VIR) Could Rally 186.41%: Here's is How to Trade
The consensus price target hints at an 186.4% upside potential for Vir Biotechnology, Inc. (VIR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
02/22 18:51 EST - Zacks Investment Research
Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Tops Revenue Estimates
Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $0.86 per share versus the Zacks Consensus Estimate of a loss of $1.14. This compares to loss of $0.76 per share a year ago.
Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Tops Revenue Estimates
Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $0.86 per share versus the Zacks Consensus Estimate of a loss of $1.14. This compares to loss of $0.76 per share a year ago.
01/31 13:16 EST - Zacks Investment Research
GSK Lags Q4 Earnings, Tops Sales, Issues Upbeat '24 Guidance
GSK's revenues benefit from strong growth across all segments, especially the Shingles and RSV vaccines. The company also issues fresh 2024 guidance for all its segments.
GSK Lags Q4 Earnings, Tops Sales, Issues Upbeat '24 Guidance
GSK's revenues benefit from strong growth across all segments, especially the Shingles and RSV vaccines. The company also issues fresh 2024 guidance for all its segments.
01/15 12:47 EST - Zacks Investment Research
Vir Biotechnology (VIR) Gains 21.7% in 3 Months: Here's Why
After a major pipeline setback, Vir Biotechnology (VIR) stock gains 21.7% in three months on its restructuring plan to cut operating expenses.
Vir Biotechnology (VIR) Gains 21.7% in 3 Months: Here's Why
After a major pipeline setback, Vir Biotechnology (VIR) stock gains 21.7% in three months on its restructuring plan to cut operating expenses.
12/06 16:05 EST - Business Wire
Vir Biotechnology to Present at J.P. Morgan 2024 42nd Annual Healthcare Conference
SAN FRANCISCO--(BUSINESS WIRE)---- $VIR #JPM2024--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Vir's Chief Executive Officer, will present at the J.P. Morgan 2024 42nd Annual Healthcare Conference on Wednesday, January 10, at 3:45 p.m. PT / 6:45 p.m. ET. A live webcast of the presentation can be accessed under Events & Presentations in the Investors section of the Vir website at www.vir.bio and will be archived there for 30 days. About Vir Biotechnology Vi.
Vir Biotechnology to Present at J.P. Morgan 2024 42nd Annual Healthcare Conference
SAN FRANCISCO--(BUSINESS WIRE)---- $VIR #JPM2024--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Vir's Chief Executive Officer, will present at the J.P. Morgan 2024 42nd Annual Healthcare Conference on Wednesday, January 10, at 3:45 p.m. PT / 6:45 p.m. ET. A live webcast of the presentation can be accessed under Events & Presentations in the Investors section of the Vir website at www.vir.bio and will be archived there for 30 days. About Vir Biotechnology Vi.
11/30 06:10 EST - InvestorPlace
7 Small-Cap Stocks to Buy BEFORE the Year-End Rally
Small-cap stocks to buy offer a window into the future of the global economy, encapsulating companies with market capitalizations upwards of $250 million and $2.5 billion. These are the potential giants of tomorrow, starting as small-caps and gradually ascending to large or even mega-cap status through consistent earnings expansion.
7 Small-Cap Stocks to Buy BEFORE the Year-End Rally
Small-cap stocks to buy offer a window into the future of the global economy, encapsulating companies with market capitalizations upwards of $250 million and $2.5 billion. These are the potential giants of tomorrow, starting as small-caps and gradually ascending to large or even mega-cap status through consistent earnings expansion.
11/27 08:45 EST - MarketBeat
From laggards to leaders: Small caps on the rise
Stocks driving that large-cap index performance include names you've become familiar with this year, such as Nvidia Corp. NASDAQ: NVDA, Tesla Inc. NASDAQ: TSLA and Meta Platforms Inc. NASDAQ: META, but also Royal Caribbean Cruises Ltd. NYSE: RCL and PulteGroup Inc. NYSE: PHM.
From laggards to leaders: Small caps on the rise
Stocks driving that large-cap index performance include names you've become familiar with this year, such as Nvidia Corp. NASDAQ: NVDA, Tesla Inc. NASDAQ: TSLA and Meta Platforms Inc. NASDAQ: META, but also Royal Caribbean Cruises Ltd. NYSE: RCL and PulteGroup Inc. NYSE: PHM.
11/10 08:00 EST - Business Wire
Vir Biotechnology to Present Late-Breaking Data from Its Ongoing Phase 2 Chronic Hepatitis B and Delta Trials at AASLD's The Liver Meeting® 2023
SAN FRANCISCO--(BUSINESS WIRE)---- $VIR #HBV--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it will be presenting new data from its Phase 2 trials evaluating the potential clinical impact that VIR-3434 and VIR-2218 could have for chronic hepatitis B (CHB) and chronic hepatitis delta (CHD) patients at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, taking place in Boston, MA, from November 10-14, 2023. These include one late-breaking poster presentation and on.
Vir Biotechnology to Present Late-Breaking Data from Its Ongoing Phase 2 Chronic Hepatitis B and Delta Trials at AASLD's The Liver Meeting® 2023
SAN FRANCISCO--(BUSINESS WIRE)---- $VIR #HBV--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it will be presenting new data from its Phase 2 trials evaluating the potential clinical impact that VIR-3434 and VIR-2218 could have for chronic hepatitis B (CHB) and chronic hepatitis delta (CHD) patients at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, taking place in Boston, MA, from November 10-14, 2023. These include one late-breaking poster presentation and on.
11/02 21:42 EST - Seeking Alpha
Vir Biotechnology, Inc. (VIR) Q3 2023 Earnings Call Transcript
Vir Biotechnology, Inc. (NASDAQ:VIR ) Q3 2023 Results Conference Call November 2, 2023 4:30 PM ET Company Participants Sasha Damouni Ellis - Executive Vice President, Chief Corporate Affairs Officer Marianne De Backer - Chief Executive Officer Phil Pang - Chief Medical Officer Sung Lee - Chief Financial Officer Conference Call Participants Gena Wang - Barclays Paul Choi - Goldman Sachs Patrick Trucchio - H. C. Wainwright Nik Gasic - Leerink Partners Eva Privitera - TD Cowen Joseph Stringer - Needham & Company Operator Hello, and welcome to Vir Biotechnology's Third Quarter 2023 Financial Results and Business Update Call.
Vir Biotechnology, Inc. (VIR) Q3 2023 Earnings Call Transcript
Vir Biotechnology, Inc. (NASDAQ:VIR ) Q3 2023 Results Conference Call November 2, 2023 4:30 PM ET Company Participants Sasha Damouni Ellis - Executive Vice President, Chief Corporate Affairs Officer Marianne De Backer - Chief Executive Officer Phil Pang - Chief Medical Officer Sung Lee - Chief Financial Officer Conference Call Participants Gena Wang - Barclays Paul Choi - Goldman Sachs Patrick Trucchio - H. C. Wainwright Nik Gasic - Leerink Partners Eva Privitera - TD Cowen Joseph Stringer - Needham & Company Operator Hello, and welcome to Vir Biotechnology's Third Quarter 2023 Financial Results and Business Update Call.
11/01 12:47 EST - Zacks Investment Research
GSK Beats on Q3 Earnings and Sales, Raises 2023 Guidance
GSK's revenues benefit from strong growth across the Specialty Medicines and Vaccines segments. The company raises guidance for earnings and sales on the back of strong RSV vaccine sales.
GSK Beats on Q3 Earnings and Sales, Raises 2023 Guidance
GSK's revenues benefit from strong growth across the Specialty Medicines and Vaccines segments. The company raises guidance for earnings and sales on the back of strong RSV vaccine sales.
10/27 12:31 EST - InvestorPlace
3 Bill Gates Stocks to Buy for Billionaire-Like Returns
When investors think of Bill Gates stocks, they inevitably come up with Microsoft (NASDAQ: MSFT ), the software company he co-founded with Paul Allen in 1975 in Albuquerque. However, as Gates has spent less time around Microsoft's business, the billionaire has significantly diversified his investment portfolio.
3 Bill Gates Stocks to Buy for Billionaire-Like Returns
When investors think of Bill Gates stocks, they inevitably come up with Microsoft (NASDAQ: MSFT ), the software company he co-founded with Paul Allen in 1975 in Albuquerque. However, as Gates has spent less time around Microsoft's business, the billionaire has significantly diversified his investment portfolio.
10/23 02:50 EST - InvestorPlace
7 Biotech Stocks to Get In Now Before Investors Catch On
Biotechnology is the source of some of our strongest and growing revolutions. Gene technology allows us to cure incurable diseases and make miracles happen with living organisms.
7 Biotech Stocks to Get In Now Before Investors Catch On
Biotechnology is the source of some of our strongest and growing revolutions. Gene technology allows us to cure incurable diseases and make miracles happen with living organisms.
10/05 16:30 EST - GlobeNewsWire
Vir Biotechnology to Provide Business Update and Report Third Quarter 2023 Financial Results on November 2, 2023
SAN FRANCISCO, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the third quarter ended September 30, 2023, on November 2, 2023. The Company will host a conference call at 4:30 p.m.
Vir Biotechnology to Provide Business Update and Report Third Quarter 2023 Financial Results on November 2, 2023
SAN FRANCISCO, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the third quarter ended September 30, 2023, on November 2, 2023. The Company will host a conference call at 4:30 p.m.